Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast can
 

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

More...

Re: Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast
 

Wow, now that is cool! We could self-administer our Neulasta AND later on in our treatment our Herceptin!